Emilia Simeonova, PhD (Economics from Columbia University in 2008) joined Johns Hopkins Carey Business School in 2013 from Tufts University. Between 2011-2012 she was a research fellow at the Center for Health and Wellbeing at Princeton University. Emilia’s research interests in the economics of health care delivery, patient adherence to therapy and the interaction between physicians and patients, racial disparities in health outcomes, the long-term effects of shocks to children's health and intergenerational transmission of health. Her research has been funded by the National Institutes of Health, the National Science Foundation, the Swedish Research Council and the Danish Academy of Sciences.
Emily Frye is Director for Cyber Integration at the Homeland Security Center at The MITRE Corporation. She is an expert on homeland security, critical infrastructure and cybersecurity. Frye’s work has helped define and explore options for the future of comprehensive, nationwide cybersecurity approaches across both public and private sectors, bridge the divide between federal and state government on cybersecurity initiatives, and strengthen public-private partnerships in support of critical infrastructure security and resilience. Frye has served on both the Long-Range Planning Committee for the Section of Science & Technology of the American Bar Association, and as advisor to the Diversity Committee of the American Bar Association. She is an accomplished speaker and moderator, and has written about issues relating to critical infrastructure, national resilience, digital technology, national security, privacy, economic impacts of cybersecurity, and the role of insurance in Critical Infrastructure Protection. She received her Doctor of Jurisprudence degree from George Mason University and her undergraduate degree from William & Mary. Her speaking appearances include a cybersecurity conference hosted by the Atlantic Council in Poland and Xconomy’s Cyber Madness. She has also written in The Hill on the need for an international cyber court, and been quoted by Slate and CybersecurityTV.
Clinical Professor of PsychiatryUniversity of California, Los Angeles (UCLA), Health Sciences
Depression, Stress, Anxiety, Relationships
Dr. Eric Bernicker is board certified by the American Board of Internal Medicine in medical oncology. He completed his medical training, a residency in internal medicine, and a fellowship in hematology at Baylor College of Medicine. He also completed a fellowship in medical oncology at MD Anderson Cancer Center. Bernicker is the primary investigator for a number of clinical trials looking at different novel therapies for lung cancer, including immunotherapy. His main clinical focus is on solid tumor oncology, specifically cancers that arise in the thorax such as lung cancer, mesothelioma, head, and neck cancer, and uveal melanomas. He is also interested in targeted therapy for specific mutations that can lead to more personalized treatments for patients battling cancer. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Erica Ollmann Saphire, Ph.D. is a Professor of the La Jolla Institute for Immunology and one of the world’s leading experts in pandemic and emerging viruses, such as Ebola, Marburg and Lassa. Dr. Saphire directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), an NIH-funded Center of Excellence in Translational Research. The VIC unites 43 previously competing academic, industrial and government labs across five continents to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Dr. Saphire's research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for developing antibody-based treatments. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa. Dr. Saphire is the recipient of numerous accolades and grants, including the Presidential Early Career Award in Science and Engineering presented by President Obama at the White House; the Gallo Award for Scientific Excellence and Leadership from the Global Virus Network; young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, American Society for Biochemistry and Molecular Biology, and the MRC Centre for Virus Research in the United Kingdom; the Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. Dr. Saphire has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from the German research foundation, Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy. Dr. Saphire received a B.A. in biochemistry and cell biology and ecology and evolutionary biology from Rice University in Houston, Texas, and a Ph.D. in molecular biology from Scripps Research. She stayed on at Scripps Research as a Research Associate to conduct postdoctoral research and rose through the ranks to become a Professor in the Department of Immunology and Microbiology. In early 2019, Dr. Saphire joined La Jolla Institute for Immunology to establish a molecular imaging facility for cryo-electron microscopy (cryo-EM) at the Institute. The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate.
Ernest Goss is the Jack MacAllister Chair in Regional Economics at Creighton University and served as the initial director for Creighton’s Institute for Economic Inquiry. He is also principal of the Goss Institute in Denver, Colo. Goss received his Ph.D. in economics from The University of Tennessee in 1983 and is a former faculty research fellow at NASA’s Marshall Space Flight Center. He was a visiting scholar with the Congressional Budget Office for 2003-2004, and has testified before the U.S. Congress, the Kansas Legislature, and the Nebraska Legislature. In the fall of 2005, the Nebraska Attorney General appointed Goss to head a task force examining gasoline pricing in the state.
Professor & Director - Stem Cell Regenerative Med.Sanford Burnham Prebys Medical Discovery Institute
Stem Cells, Spinal Cord Injury, Parkinson's Disease, ALS, Bipolar Disorder
Former First Lady Nancy Reagan said NO to drugs but YES to stem cell research. Where are we now? @sbpdiscovery researcher explains.
Emergency medicineUniversity of Texas Health Science Center at Houston
Hot cars, Water Safety, Drowning, distracted driving, Holiday toy safety
Beaches, lakes, and pools are great ways to beat the heat but there are precautions to take before reaching for that swimsuit, said Gabriella Cardone, MD, an emergency medicine pediatrician with McGovern Medical School at UTHealth and attending physician at Children’s Memorial Hermann Hospital. “Taking the time to follow some basic precautions will keep you and your loved ones safe in the water all summer long,” Cardone said. Before engaging in aquatic activities, make sure everyone knows how to swim or has an approved life jacket. Water noodles, inner tubes, or water wings do not count. Tragically, there are approximately 3,536 fatal unintentional drownings in the U.S. every year, which is an average of 10 deaths a day, according to the Centers for Disease Control and Prevention. “Children should learn how to swim by age 4 and their parents should learn cardiopulmonary resuscitation or CPR in case of emergency,” Cardone said.
Practicing internal medicine physician who has served as chairman and CEO of the Virginia Mason Health System in Seattle since 2000. He is also chair of the National Patient Safety Foundation Lucian Leape Institute and immediate past chair of the Institute for Healthcare Improvement Board of Directors. During his tenure as chief executive, Virginia Mason has become a national leader in quality, safety and innovation resulting from its Toyota Production System-inspired lean management methodology, the Virginia Mason Production System. To schedule an interview with Dr. Kaplan, contact Virginia Mason Media Relations.
Dr. Kumar is a board-certified pediatrician with nearly 20 years of experience. He earned his Doctor of Medicine degree from Johns Hopkins University School of Medicine, where he also completed his internship and residency in pediatrics. Dr. Kumar is a fellow of the American Academy of Pediatrics and is active in the Maryland chapter of the organization.
Associate Professor of Accounting, Health Policy, and ManagementJohns Hopkins University Carey Business School
healthcare administration, finace, Accounting, healthcare pricing, Healthcare Management, Health Policy, Healthcare Access, healthcare business, healthcare decision making, Healthcare economics, healthcare information, Healthcare Law
Ge Bai, PhD, CPA is an associate professor of Accounting at Johns Hopkins Carey Business School and associate professor of Health Policy & Management at Johns Hopkins Bloomberg School of Public Health. She is an expert on health care pricing, policy, and management. Dr. Bai has written for the Wall Street Journal and published her studies in leading academic journals such as the New England Journal of Medicine, JAMA, JAMA Internal Medicine, Annals of Internal Medicine, and Health Affairs. Her work has been widely featured in ABC, Atlantic, CBS, CNN, Forbes, Fox News, Los Angeles Times, NBC, New York Times, NPR, The Guardian, U.S. News & World Report, Wall Street Journal, Washington Post, and other media and used in government regulations and congressional testimony.
At Ohio State, Dr. Paz leads all seven health science colleges and serves as CEO of the $4-billion Wexner Medical Center enterprise, which includes seven hospitals, a nationally ranked college of medicine, over 20 research institutes, multiple ambulatory sites, an accountable care organization, and a health plan. Before joining OSU in June 2019, Dr. Paz was executive vice president and chief medical officer at Aetna where he led clinical strategy and policy at the intersection of all of Aetna’s domestic and global businesses. He reported to Aetna’s chairman and CEO and was a member of its executive committee. Prior to joining Aetna in 2014, Dr. Paz served as president and CEO of the Penn State Hershey Health System, senior vice president for health affairs at the Pennsylvania State University, and dean of its College of Medicine for eight years. Before his appointment at Penn State, he spent eleven years as dean of the Robert Wood Johnson Medical School and CEO of the Robert Wood Johnson University Medical Group. Dr. Paz received his bachelor's degree from the University of Rochester, a master of science in life science engineering from Tufts University, and his medical degree from the University of Rochester School of Medicine and Dentistry. He completed his residency at Northwestern University, where he served as chief medical resident. Dr. Paz was a Eudowood Fellow in pulmonary and critical care medicine at Johns Hopkins Medical School. In addition, he was a post-doctoral fellow in environmental health science at Johns Hopkins School of Hygiene and Public Health.
Harvinder Gill is a graduate advisor, associate professor and Whitacre Endowed Chair of Science and Engineering in the Department of Chemical Engineering within the Texas Tech University Edward E. Whitacre Jr. College of Engineering. He directs the Gil Lab where he and his colleagues perform fundamental and translational research in the fields of drug delivery, vaccines, immunotherapy, and nanomedicine to help address some of the pressing biomedical challenges facing human health. His research integrates the knowledge and tools from various disciplines including engineering, chemistry, biology, immunology, recombinant engineering, and micro-nano-technology. Gill currently works to discover innovative drug and vaccine delivery platforms aimed at maximizing stimulation of mucosal immunity in order to address the challenges related to influenza and HIV infectious diseases as well as developing a delivery system for localized delivery of cancer drugs directly into oral tumors. Dr. Gill also is working on developing a delivery method to eliminate peanut allergies through a grant from the NIH, working to transform pollen grain shells into vehicles for delivery of allergy vaccines, and using microneedles to eliminate the need for regular needles to deliver vaccines. Gill earned his bachelor's degree in chemical engineering from Panjab University in 1994 and his doctorate in bioengineering from the Georgia Institute of Technology in 2007.
After graduating from the Yale School of Medicine, I completed an internship, residency and fellowship in Hematology-Oncology at Bellevue Hospital and NYU Medical Center. These experiences taught me that the key to success in medicine is to be patient focused and put the patient’s needs first - values that I continue to hold and practice every day. I am certified in Internal Medicine by the American Board of Internal Medicine, and by the Hematology and Oncology Boards. Since 1986, I was on the NYU faculty in medical oncology, rising to full professor before moving to the Yale Cancer Center in 2010, where I was the Associate Director for Clinical Research and head of GI Oncology until joining Rutgers Cancer Institute. My clinical expertise and research interests are dedicated to early drug development and clinical pharmacology, focused on tumors of the gastrointestinal tract. I have led numerous clinical trials and have been at the forefront of clinical research in GI Oncology and have been instrumental in the approval of eight new drugs for the treatment of colon cancer. I have authored more than 150 peer-reviewed articles on cancer therapy, new drug development and clinical trials and have presented many of these study results at national meetings. I have had two R01 funded research projects on cancer pharmacodynamics and was recently awarded a Lead Academic Participating Site Grant to support NCI sponsored clinical trials. I also have been very involved with the NCI National Clinical Trials Network (NCTN) and have chaired ten phase 2 and phase 3 studies in the NCI cooperative groups. Since 2013, I have chaired the GI Cancer Committee for SWOG (formerly, Southwestern Oncology Group), one of the four NCTN cooperative groups. Together with my SWOG and NCTN colleagues, we strive to design and conduct the studies that set standards of care for pioneering new treatments in cancer care. Other professional activities include reviewing scientific publications and grant applications in my capacity as Associate Editor for the Journal of the National Cancer Institute and Journal of GI Oncology. I also regularly review manuscripts for Journal of Clinical Oncology, Cancer, British Medical Journal and Lancet. I review grants for the NCI and the Cancer Prevention and Research Institute of Texas. I am also a Medical Director of the Chemotherapy Foundation. In my free time, I am an avid marathon runner and century cyclist. Rutgers Cancer Institute has a rich history of conducting innovative and groundbreaking cancer research, and, together with RWJBarnabas Health, we offer unparalleled knowledge, clinical care and resources for cancer patients and their families close to home. I feel privileged to work alongside the many expert cancer providers and compassionate staff. Our overall mission is to deliver outstanding cancer care and to achieve the best outcomes for our patients in New Jersey and beyond. My vision is to bring the very best in treatment via clinical trials and clinical research to the people of New Jersey and to make us a treatment destination venue for patients around the world. Positions: Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey Chief, GI Medical Oncology Director of Cancer Clinical Research, Oncology Service Line, RWJBarnabas Clinical Expertise: GI Cancers, colon cancer, pancreatic cancer, biliary cancers, neuroendocrine tumors Honors: Fullbright Scholar (Brussels, Belgium), 1985-6 Best Doctor, New York Magazine or Connecticut Magazine, 1997-2017 America’s Top Doctors, 2003-2017 Top Oncology Doctors in US, 2005-2017 Grant reviewer for NCI and Cancer and Prevention Research Institute of Texas Chair, New York Cancer Society, 2004-2006 President, International Society of Clinical Oncology, 2017-2019
Associate Professor of Neurosurgery, Radiation oncUniversity of California, Los Angeles (UCLA), Health Sciences
Neurosurgery, Neuroscience, Brain Tumor, Hearing, Balance, Radiosurgery, UCLA, David Geffen School of Medicine at UCLA
Isaac Yang, M.D., is a nationally renowned neurosurgeon specializing in brain tumors, superior semicircular canal dehiscence (SSCD), and skull base brain surgery at UCLA. Yang is a board-certified neurosurgeon and director of medical student education for the UCLA Department of Neurosurgery; an associate professor of neurosurgery, head and neck surgery, and radiation oncology at the David Geffen School of Medicine at UCLA, and a principal investigator at the UCLA brain tumor laboratory. Yang is highly sought out by peers, patients and the media for his expertise in neurological diseases and brain health. He has made multiple TV appearances on Good Morning America, CBS' The Doctors, Dr. Drew LifeChangers, and several national news outlets. Originally from Lodi, Calif., Yang developed an interest in neurobiology as an undergraduate. He earned his bachelor’s degree with Phi Beta Kappa from the University of California, Berkeley. His training followed with a medical degree from the David Geffen School of Medicine at UCLA. Yang completed a neurological surgery residency at the University of California San Francisco, as well as an NRSA NIH-funded F32 postdoctoral brain tumor research fellowship. Yang’s clinical focus has been primarily on brain tumors, both glioblastoma and skull base tumors. His research efforts have examined antigen expression and manipulation of the immune response to glioblastoma. His work was recognized by a UCSF Clinical and Translational Scientist Training Award and the CNS Dandy Clinical Research Fellowship. Yang has been the recipient of several distinguished regional and national awards, including the UCSF Medical Center 2010 Exceptional Physician Award, the AANS Integra Brain Tumor Research Award, San Francisco Neurological Society Edwin Boldrey Award for Basic Science Research, American Academy of Neurological and Orthopedic Surgeons Research Award, Kaiser Award for Clinical Research, the national AANS Leksell Radiosurgery Award, and the Tumor Section Ronald L. Bittner Award on Brain Tumor Research. Yang has published more than 150 publications in peer-reviewed journals and authored more than half a dozen book chapters. At UCLA, he is investigating the use of nanoparticles and nanotechnology for their application in brain tumor immunotherapy and vaccines. Dr. Isaac Yang is dedicated to improving the care and treatment of all patients undergoing neurosurgery. If interested please follow Dr. Yang on Facebook at Isaac Yang UCLA Neurosurgery or find his most recent book, Service Minded Physician, on Amazon.
URI’s Isaac Ginis uses computer model to predict the power of storms. The 2019 hurricane season officially kicked off June 1. Predicting the severity of a hurricane can mean the difference between life and death. URI Professor of Oceanography Isaac Ginis makes it his business to predict the power of these ferocious storms with a computer model so successful it was adopted by the National Weather Service. Ginis’s research efforts have resulted in pioneering advances in modeling of the tropical cyclone-ocean interactions that have led to significant improvements in hurricane intensity forecast skills. Ginis’s research group has contributed to the development of the HWRF hurricane model used by the U.S. National Hurricane Center and Joint Typhoon Warning Center for operational forecasting of tropical cyclones in all ocean basins. He is currently leading a project funded by the U.S. Department of Homeland Security Coastal Resilience Center of Excellence to develop advanced modeling capabilities for more accurate representation of hurricane hazards and impacts in Southern New England. This project allows DHS and other agencies to better understand the consequences of coastal and inland hazards associated with extreme hurricanes and Nor’easters and to better prepare coastal communities for future risks.